Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	1.11T
Revenue (ttm)	1.20T
Net Income (ttm)	-116.55B
Shares Out	75.96M
EPS (ttm)	-1,880.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	208,987
Average Volume	471,797
Open	14,620
Previous Close	14,610
Day's Range	14,600 - 14,950
52-Week Range	9,260 - 15,990
Beta	0.38
RSI	54.39
Earnings Date	Mar 20, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.